Studies
PGRN Antidepressant Medication Pharmacogenomic Study (AMPS)
PGRN Antidepressant Medication Pharmacogenomic Study (AMPS)
Request Access
Overview
Selected Publications (5)
Glycine and a Glycine Dehydrogenase (GLDC) SNP as Citalopram/Escitalopram Response Biomarkers in Depression: Pharmacometabolomics‐Informed Pharmacogenomics
Y. Ji, S. Hebbring, Hongjie Zhu, et al.. (2011). Clinical Pharmacology & Therapeutics. Cited 151 times.
https://doi.org/10.1038/clpt.2010.250
Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics
Y. Ji, J. Biernacka, S. Hebbring, et al.. (2012). The pharmacogenomics journal. Cited 71 times.
https://doi.org/10.1038/tpj.2012.32
FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder
Katarzyna A Ellsworth, Irene Moon, B. Eckloff, et al.. (2013). Pharmacogenetics and Genomics. Cited 59 times.
https://doi.org/10.1097/FPC.0b013e32835dc133
Merging pharmacometabolomics with pharmacogenomics using ‘1000 Genomes’ single-nucleotide polymorphism imputation: selective serotonin reuptake inhibitor response pharmacogenomics
R. Abo, S. Hebbring, Y. Ji, et al.. (2012). Pharmacogenetics and Genomics. Cited 52 times.
https://doi.org/10.1097/FPC.0b013e32835001c9
Catechol O-methyltransferase pharmacogenomics and selective serotonin reuptake inhibitor response
Y. Ji, J. Biernacka, K. Snyder, et al.. (2010). The Pharmacogenomics Journal. Cited 34 times.
https://doi.org/10.1038/tpj.2010.69
